Is Privia Health Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Privia Health Group, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is considered overvalued, with a P/E ratio of 181, a Price to Book Value of 4.29, and an EV to EBITDA of 82.17, all of which are substantially higher than typical industry benchmarks.
In comparison to its peers, Privia Health's P/E ratio is markedly higher than Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59, both of which are classified as fairly valued. Additionally, its EV to EBITDA ratio of 82.17 is also elevated compared to the industry, further supporting the overvaluation verdict. Notably, despite the company's strong short-term performance, with a 1-year return of 38.45% compared to the S&P 500's 14.08%, the long-term outlook appears less favorable, as evidenced by a 3-year return of -24.4% versus the S&P 500's 81.19%.